|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 205/04 | |
| A61K 31/397 | |||
| A61P 29/00 | |||
| A61P 31/06 | |||
| A61P 31/08 | |||
| A61P 21/00 |
| (11) | Number of the document | 2379499 |
| (13) | Kind of document | T |
| (96) | European patent application number | 09793424.4 |
| Date of filing the European patent application | 2009-12-17 | |
| (97) | Date of publication of the European application | 2011-10-26 |
| (45) | Date of publication and mention of the grant of the patent | 2014-04-09 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2009/068352 |
| Date | 2009-12-17 |
| (87) | Number | WO 2010/080455 |
| Date | 2010-07-15 |
| (30) | Number | Date | Country code |
| 203051 P | 2008-12-18 | US |
| (72) |
DE LA CRUZ, Marilyn, US
KARPINSKI, Piotr, H., US
LIU, Yugang, US
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | Hydrochloride salt of 1-(4-(1-((E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl)-2-ethyl-benzyl)-azetidine-3-carboxylic acid |
| Hydrochloride salt of 1-(4-(1-((E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl)-2-ethyl-benzyl)-azetidine-3-carboxylic acid |